VITA Orthovita, Inc. (MM)

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Schedule 14D-9

SOLICITATION/RECOMMENDATION STATEMENT

UNDER SECTION 14(D)(4) OF THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 3)

Orthovita, Inc.

(Name of Subject Company)

Orthovita, Inc.

(Names of Persons Filing Statement)

Common Stock

($0.01 par value)

(Title of Class of Securities)

CUSIP 68750U102

(CUSIP Number of Class of Securities)

Christine J. Arasin, Esquire

Vice President and General Counsel

Orthovita, Inc.

77 Great Valley Parkway

Malvern, PA 19355

(610) 640-1775

(Name, address, and telephone numbers of person authorized to receive

notices and communications on behalf of the persons filing statement)

With copies to:

Richard A. Silfen, Esquire

Douglas P. Howard, Esquire

Duane Morris LLP

30 South 17th Street

Philadelphia, Pennsylvania 19103

(215) 979-1000

This Amendment No. 3 amends and supplements the Solicitation/Recommendation Statement on Schedule 14D-9 initially filed with the Securities and Exchange Commission (the “SEC”) on May 27, 2011, as amended by Amendment No. 1 thereto filed with the SEC on May 27, 2011 and Amendment No. 2 thereto filed with the SEC on June 3, 2011 (as the same may be further amended or supplemented from time to time, the “Schedule 14D-9”) by Orthovita, Inc., a Pennsylvania corporation (the “Company” or “Orthovita”). The Schedule 14D-9 relates to the tender offer by Owl Acquisition Corporation, a Delaware corporation (the “Purchaser”) and a wholly-owned indirect subsidiary of Stryker Corporation, a Michigan corporation (“Parent”), to purchase all of the outstanding shares of the Company’s common stock, par value $0.01 per share, at a purchase price of $3.85 per share, net to the seller in cash, without interest thereon and less any applicable withholding taxes, upon the terms and subject to the conditions set forth in the Offer to Purchase, dated May 27, 2011 (as amended or supplemented from time to time, the “Offer to Purchase”), and in the related Letter of Transmittal (as amended or supplemented from time to time, the “Letter of Transmittal”) (which offer, upon such terms and subject to such conditions, as it and they may be amended or supplemented from time to time, constitutes the “Offer”). Copies of the Offer to Purchase and Letter of Transmittal are filed as Exhibit (a)(1)(A) and Exhibit (a)(1)(B) to the Schedule 14D-9, respectively, and are incorporated herein by reference. Any capitalized term used, but not otherwise defined, herein shall have the meaning ascribed to such term in the Schedule 14D-9.

This Amendment No. 3 is being filed to reflect certain updates as reflected below.

The section entitled “Certain Litigation” under Item 8 is hereby amended and supplemented by adding the following paragraph after the last paragraph of such section:

“On June 6, 2011, Adolphina Van Barel (“Van Barel”), a purported shareholder of Orthovita, filed a putative class action in the United States District Court for the Eastern District of Pennsylvania, captioned Van Barel v. Koblish et al. , Case No. 11-3652, naming as defendants the individual members of the Orthovita Board, Orthovita, Parent and the Purchaser. On behalf of a putative class of Orthovita shareholders and derivatively on behalf of Orthovita, Van Barel asserts claims against (i) the individual directors of Orthovita for violations of Sections 14(d)(4) and 14(e) of the Exchange Act for material misrepresentations in, and omission of material information from, the Schedule 14D-9 and (ii) the individual directors of Orthovita for breaches of fiduciary duties in connection with the Offer and the Merger, and, on behalf of a putative class of Orthovita shareholders, Van Barel asserts claims against Orthovita, Parent and the Purchaser for aiding and abetting the breaches of fiduciary duties by the individual directors of Orthovita. Van Barel seeks declaratory relief, injunctive relief, rescission, damages, costs, including a reasonable allowance for the fees and expenses of attorneys and experts, and other equitable relief. Orthovita believes that this action is without merit and intends to defend its position in this matter vigorously.”

1

Item 9 is hereby amended and supplemented by adding the following exhibit, filed as part of the Schedule 14D-9:

2

SIGNATURE

After due inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date: June 8, 2011

3

Orthovita, Inc. (MM) (NASDAQ:VITA)
Historical Stock Chart
From Apr 2024 to May 2024

Orthovita, Inc. (MM) (NASDAQ:VITA)
Historical Stock Chart
From May 2023 to May 2024